Vanderbilt-Ingram Cancer Center
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Vanderbilt-Ingram Cancer Center sits in the top decile of US sponsors by registered trial count (#157 of 15,742 sponsors by registered trial count).
Vanderbilt-Ingram Cancer Center: 189 sponsored US clinical trials, 28 recruiting.
Vanderbilt-Ingram Cancer Center sponsors 189 registered US clinical trials on ClinicalTrials.gov, 28 of them currently recruiting, and 87 completed. 7 of these trials are in Phase 3-4 (later-stage) and 97 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Lung Cancer, with 10 trials.
Top-decile sponsor footprint
Vanderbilt-Ingram Cancer Center ranks in the top decile of sponsors by registered trial count (#157 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
87 of 152 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (57.2%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
189 total, page 1 of 4
Safety and Feasibility of Nivolumab-IRDye800CW in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC)
NCT07460765
Study Evaluating [18F]NOTA-ABY030 for Safety and Tolerability of Indeterminate Primary and/or Metastatic Disease in Head and Neck Squamous Cell Carcinoma
NCT07217028
Pilot Study of [68Ga]Ga-ABY-025 Imaging in Patients Undergoing Treatment With HER2-targeted Therapy
NCT06828588
High-Resolution PET-CT Imaging for Surgical Margin Visualization
NCT06915454
Window Trial of Fluorescently Labeled Panitumumab (Panitumumab-IRDye800) in Head and Neck Cancer
NCT06819228
Cryodevitalization for the Treatment of Early Stage Lung Cancer, CRYSTAL Trial
NCT06593106
EBUS-TBNA vs Transbronchial Mediastinal Cryobiopsy for Adequacy of Next Generation Sequencing
NCT06105801
Eltanexor and Venetoclax in Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia
NCT06399640
Surgical Debulking Prior to Peptide Receptor Radionuclide Therapy in Well Differentiated Gastroenteropancreatic Neuroendocrine Tumors
NCT06016855
Neoadjuvant Neratinib in Stage I-III HER2-Mutated Lobular Breast Cancers
NCT05919108
Phase I/II Trial in ES-SCLC to Enhance Response to Atezolizumab Plus Chemotherapy With Total Body Irradiation
NCT06110572
A Combined Biomarker Model for Risk Stratification of Indeterminate Pulmonary Nodules
NCT06074133
Evaluating the Use of Dual Imaging Techniques for Detection of Disease in Patients With Head and Neck Cancer
NCT05945875
Evaluating 111In Panitumumab for Nodal Staging in Head and Neck Cancer
NCT05901545
Circulating Tumor DNA to Guide Changes in Standard of Care Chemotherapy
NCT05770531
Image-Based, In-Vivo Assessment of Tumor Hypoxia to Guide Hypoxia-Driven Adaptive Radiation Therapy
NCT05996432
Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer
NCT05501665
Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study
NCT05361720
Cohort to Augment the Understanding of Sarcoma Survivorship Across the Lifespan
NCT06482957
Hypofractionated Radiotherapy Followed by Surgical Resection in the Treatment of Soft Tissue Sarcomas
NCT04506008
The Clonal Hematopoiesis & Inflammation in Vasculature Registry and Biorepository
NCT06701214
Studying Health Outcomes After Treatment in Patients With Retinoblastoma
NCT03932786
Inherited CAncer REgistry
NCT03231891
Low-Dose Total Skin Electron Therapy in Treating Patients With Refractory or Relapsed Stage IB-IIIA Mycosis Fungoides
NCT02702310
Storage and Research Use of Human Bio-specimens From Melanoma Patients and Clinical Testing for Assignment of Treatment
NCT01205815
Collecting and Storing Tissue Samples From Women With or Without Breast Cancer
NCT00899301
Molecular Predictors of Cancer in Patients at High Risk of Lung Cancer
NCT00898313
Collecting and Analyzing Tissue Samples From Patients Undergoing Surgery for Non-Small Cell Lung Cancer
NCT00897117
Biomarker Platform (Virtual Nodule Clinic) for the Management of Indeterminate Pulmonary Nodules
NCT06638398
Rigosertib Plus Pembrolizumab in Treating Patients With Unresectable/Metastatic Melanoma Refractory to PD-1 Inhibitors
NCT05764395
Improving Care After Inherited Cancer Testing
NCT04763915
COVID-19 and Cancer Consortium Registry
NCT04354701
Ifetroban in Treating Patients With Malignant Solid Tumors at High Risk of Metastatic Recurrence
NCT03694249
Early Detection of Lung Cancer
NCT03181256
BYL719 and Letrozole in Post-Menopausal Patients With Hormone Receptor-Positive Metastatic Breast Cancer
NCT01791478
Nashville Early Diagnosis Lung Cancer Project
NCT01475500
Nemtabrutinib With CAR T Therapy in Relapsed/Refractory Mantle Cell Lymphoma
NCT07673367
Pembrolizumab After Radiation Therapy and Chemotherapy in Limited Stage Small Cell Lung Cancer
NCT06140407
Chimeric Antigen Receptor (CAR) T Cell Therapy With YESCARTA in the Outpatient Setting
NCT05108805
Impact of Human-Animal Interactions on Children With Life-Threatening Conditions and Their Parents
NCT04310345
Disease Burden and Biology Using Tumor Cell Free DNA in Metastatic Kidney Cancer
NCT04883827
Metabolism Informed Smoking Treatment: The MIST RCT
NCT04590404
Effect of Artificial Tears on Radioiodine Levels in the Nasolacrimal Duct System
NCT04327999
Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal, Fallopian Tube Cancers
NCT03924245
Navigation Endoscopy to Reach Indeterminate Lung Nodules Versus Trans-Thoracic Needle Aspiration
NCT04250194
Assessing Benefits of NIRAF Detection for Identifying Parathyroid Glands During Total Thyroidectomy.
NCT04281875
Evaluating Impact of NIRAF Detection for Identifying Parathyroid Glands During Parathyroidectomy
NCT04299425
Enterade in Carcinoid/Non-Carcinoid Syndrome Neuroendocrine Tumor Patients With Quality of Life Limiting Bowel Frequency
NCT04073017
Central Pain Syndrome in Survivors of Head and Neck Cancer
NCT04128267
Yoga Intervention in Head and Neck Cancer Patients Undergoing Concurrent Chemo-Radiation
NCT04146779
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 46 |
| Phase 2 | 51 |
| Phase 3 | 4 |
| Phase 4 | 3 |
What is open in the Vanderbilt-Ingram Cancer Center pipeline
28 recruiting of 189 indexed (15% open); 87 completed (46%).
Phase mix: 7 late (III/IV) vs 97 early (I/II) (early-phase heavy).
Top condition: Lung Cancer (10 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Vanderbilt-Ingram Cancer Center: open-pipeline peers nationwide
Peers matched on 189 registered trials and 15% open enrollment, not the therapeutic-area sidebar.
Vanderbilt-Ingram Cancer Center sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 189 trials (± recruiting share)
- Nationwide Children's Hospital · 188 trials · 15% recruiting
- Vertex Pharmaceuticals Incorporated · 191 trials · 10% recruiting
- Arizona State University · 187 trials · 15% recruiting
- Johns Hopkins Bloomberg School of Public Health · 187 trials · 14% recruiting
Sponsors near 15% open enrollment (± trial volume)
- Dompé Farmaceutici S.p.A · 15% recruiting · 27 trials
- University of Rochester · 15% recruiting · 636 trials
- Loma Linda University · 15% recruiting · 237 trials
- University of Washington · 15% recruiting · 1,048 trials
Related
What to do with this Vanderbilt-Ingram Cancer Center page
189 registered trials is a research-attention snapshot, not an endorsement of Vanderbilt-Ingram Cancer Center or any single study.
- 28 of Vanderbilt-Ingram Cancer Center's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Lung Cancer is the condition Vanderbilt-Ingram Cancer Center studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Lung Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Vanderbilt-Ingram Cancer Center pipeline card: 189 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.